Healthcare Deals: Big Pharma, Megamergers & IPOs

Download IconDownload Print IconPrint

Healthcare Deals: Big Pharma, Megamergers & IPOs

Cambridge, MA
Speaking Engagement
Pharmaceutical and biotechnology companies had a blockbuster year in 2014, with a record number of IPOs and continuing pace of mergers and acquisitions. Starting out 2015 in a similar vein, large pharma companies such as Shire and Pfizer began purchasing companies in the space. With the IPO market facing macroeconomic headwinds, could we see more acquisitions of smaller emerging biotechnology companies by larger players? Is 2015 the year where we will see megamergers that have failed to occur—such as Pfizer and AstraZeneca last year? Could private equity take interest in more early stage pharmaceutical companies? What could this mean for M&A activity in the space for the coming year?

Register to watch the live video roundtable discussion of how cancer drugs and orphan drugs are often attractive, but what other areas will be hot in 2015? Will we see a larger pharmaceutical megamerger? Or will smaller companies continue to go at it on their own? What will this mean for early-stage biopharma? And who will be the big consolidators in the space?

Read More About the Event

You May Be Interested In

FIA Law & Compliance Division Conference 2024

April 24–26, 2024
Speaking Engagement

18th Annual Flagship Conference on Economic Sanctions Enforcement and Compliance

April 29, 2024
Speaking Engagement

Essentials of the European Union’s Artificial Intelligence Act

May 2, 2024
Webinar
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel